Neuroendocrine Tumor Treatment Market Size & Share, by End-user (Hospitals, Clinics); Therapy (Somatostatin Analogs, Chemotherapy, Cancer Immunotherapy, Targeted Therapy); Indication (Lungs, Pancreas, Gastrointestinal) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 3846
Published Date: Aug 08, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Neuroendocrine Tumor Treatment Market

BoehringerIngelheim International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Hutchison MediPharma Limited,
AVEO Oncology
Pfizer, Inc.
IpsenPharma
Tarveda Therapeutics
Progenics Pharmaceuticals
Novartis AG
Eli Lilly & Company
Ipsen Pharma

Browse Key Market Insights with Data Illustration:

Neuroendocrine Tumor Treatment Market Size & Share | Forecast Report 2035

In the News

Eli Lilly & Company to supply its human insulin active pharmaceutical ingredient (API) to IABL at a reduced cost in order to facilitate the manufacturing of insulin in Bangladesh.
Boehringer Ingelheim teamed up with 3T Biosciences to identify and create cutting-edge cancer treatments to meet the significant unmet patient needs. Further, the collaboration will combine the industry-leading 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform from 3T Biosciences with Boehringer Ingelheim's two-pronged research approach combining cancer cell-directed and immune cell-targeting compounds.

Frequently Asked Questions (FAQ)

Increasing incidence of neuroendocrine cancer is the major factor driving the market growth.

The market size of neuroendocrine tumor treatment is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2023 â€“ 2035.

The major players in the market are BoehringerIngelheim International GmbH, Hutchison MediPharma Limited, AVEO Oncology, Pfizer, Inc., IpsenPharma, Tarveda Therapeutics, Progenics Pharmaceuticals, Novartis AG, Eli Lilly & Company, Ipsen Pharma, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Neuroendocrine Tumor Treatment Market Size & Share, by End-user (Hospitals, Clinics); Therapy (Somatostatin Analogs, Chemotherapy, Cancer Immunotherapy, Targeted Therapy); Indication (Lungs, Pancreas, Gastrointestinal) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Companies Dominating the Neuroendocrine Tumor Treatment Market

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What is the major factor driving the growth of the neuroendocrine tumor treatment market?

What would be the CAGR of the neuroendocrine tumor treatment market over the forecast period?

Who are the major players dominating the neuroendocrine tumor treatment market?

Which segment captures the largest market size in the end user segment in the neuroendocrine tumor treatment market?

Which region will provide more business opportunities for the growth of the neuroendocrine tumor treatment market in the future?